Philip Scheltens
Overview
Explore the profile of Philip Scheltens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
920
Citations
57299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamps S, Hempel H, van Amerongen S, de Bruin H, van der Linden F, Venkatraghavan V, et al.
Brain Commun
. 2025 Mar;
7(2):fcaf085.
PMID: 40046332
Cavum septum pellucidum (CSP) is commonly observed upon neuroimaging examination in individuals exposed to repetitive head impacts (RHI) and post-mortem in cases with chronic traumatic encephalopathy. Consequently, CSP has been...
2.
Wesenhagen K, de Leeuw D, Tomassen J, Gobom J, Bos I, Vos S, et al.
Alzheimers Res Ther
. 2025 Mar;
17(1):56.
PMID: 40033427
Background: We investigated how cerebrospinal fluid levels of synaptic proteins associate with memory function in normal cognition (CN) and mild cognitive impairment (MCI), and investigated the effect of amyloid positivity...
3.
Scheltens P, Atri A, Feldman H, Hansson O, Knop F, Sano M, et al.
Neurology
. 2025 Feb;
102(7_supplement_1):3350.
PMID: 39977949
Objective: We report the preliminary baseline characteristics in the ongoing phase 3 evoke and evoke+ trials investigating the safety and efficacy of oral semaglutide for early AD. Background: Semaglutide, a...
4.
Wolk D, Nelson P, Apostolova L, Arfanakis K, Boyle P, Carlsson C, et al.
Alzheimers Dement
. 2025 Jan;
21(1):e14202.
PMID: 39807681
Limbic predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) is highly prevalent in late life and a common co-pathology with Alzheimer's disease neuropathologic change (ADNC). LATE-NC is a slowly progressive, amnestic...
5.
Aye S, Johansson G, Hock C, Lannfelt L, Sims J, Blennow K, et al.
J Prev Alzheimers Dis
. 2025 Jan;
12(1):100022.
PMID: 39800469
The advancement of disease-modifying treatments (DMTs) for Alzheimer's disease (AD), along with the approval of three amyloid-targeting therapies in the US and several other countries, represents a significant development in...
6.
Cummings J, Atri A, Feldman H, Hansson O, Sano M, Knop F, et al.
Alzheimers Res Ther
. 2025 Jan;
17(1):14.
PMID: 39780249
Background: Disease-modifying therapies targeting the diverse pathophysiology of Alzheimer's disease (AD), including neuroinflammation, represent potentially important and novel approaches. The glucagon-like peptide-1 receptor agonist semaglutide is approved for the treatment...
7.
van Nifterick A, de Haan W, Stam C, Hillebrand A, Scheltens P, Van Kesteren R, et al.
Brain Commun
. 2024 Dec;
6(6):fcae423.
PMID: 39713236
Understanding the nature and onset of neurophysiological changes, and the selective vulnerability of central hub regions in the functional network, may aid in managing the growing impact of Alzheimer's disease...
8.
Le Borgne J, Gomez L, Heikkinen S, Amin N, Ahmad S, Choi S, et al.
Mol Psychiatry
. 2024 Dec;
PMID: 39633006
Due to methodological reasons, the X-chromosome has not been featured in the major genome-wide association studies on Alzheimer's Disease (AD). To address this and better characterize the genetic landscape of...
9.
Collij L, Bischof G, Altomare D, Bader I, Battle M, Garcia D, et al.
J Nucl Med
. 2024 Nov;
66(1):110-116.
PMID: 39542700
Several studies have demonstrated strong agreement between routine clinical visual assessment and quantification, suggesting that quantification approaches could support assessment by less experienced readers or in challenging cases. However, all...
10.
Aisen P, Bateman R, Crowther D, Cummings J, Dwyer J, Iwatsubo T, et al.
Alzheimers Dement
. 2024 Nov;
21(1):e14342.
PMID: 39535341
Decades of research have provided evidence that Alzheimer's disease (AD) is caused in part by cerebral accumulation of amyloid beta-protein (Aβ). In 2023, the US Food and Drug Administration gave...